Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose response of prophylactic antipsychotics

J M Davis1, J M Kane, S R Marder

  • 1Illinois State Psychiatric Institute, Chicago.

The Journal of Clinical Psychiatry
|March 1, 1993
PubMed
Summary

Regular antipsychotic medication is crucial for preventing relapse in chronic schizophrenia patients. Consistent treatment, including depot haloperidol, offers relapse prevention with fewer side effects than intermittent dosing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

International journal of clinical practice·2014
Same author

Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse.

Neuroscience·2010
Same author

Antipsychotic drug-induced weight gain: development of an animal model.

International journal of obesity (2005)·2005
Same author

The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.

Psychopharmacology·2001
Same author

Effects of benztropine on ketamine-induced behaviors in Cebus monkeys.

Behavioural pharmacology·2001
Same author

Clinical trial design issues in schizophrenic research.

The Journal of clinical psychiatry·2001

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a chronic mental illness requiring long-term management.
  • Antipsychotic medication is a cornerstone of schizophrenia treatment.
  • Relapse is common without consistent pharmacotherapy.

Purpose of the Study:

  • To review literature on oral versus depot antipsychotic medication for chronic schizophrenia.
  • To highlight considerations for optimizing treatment strategies.
  • To discuss relapse prevention and management.

Main Methods:

  • Literature review of studies on oral and depot antipsychotic medications.
  • Analysis of relapse rates, clinical significance, and side effect profiles.
  • Evaluation of dosing strategies and psychosocial rehabilitation.

Related Experiment Videos

Main Results:

  • Patients not on antipsychotics relapse within 3 years, with higher frequency and severity.
  • Regular medication administration is superior to intermittent dosing.
  • Depot haloperidol is a viable option for relapse prevention with potentially fewer adverse effects.

Conclusions:

  • Consistent antipsychotic treatment is essential for managing chronic schizophrenia.
  • Individualized treatment plans considering medication type, administration, and side effects are necessary.
  • Integrating psychosocial rehabilitation alongside regular medication improves outcomes.